60 degrees pharmaceuticals announces second quarter 2024 results

Q2 2024 net product revenues doubled year-over-year to $125 thousand sequential (quarter-over-quarter) net product revenue growth of 18.3% gross profit increased from ($124 thousand) to $35 thousand, year-over-year washington, aug. 14, 2024 (globe newswire) -- 60 degrees pharmaceuticals, inc.  (nasdaq: sxtp; sxtpw) (the “company”), a pharmaceutical company focused on developing new medicines for infectious diseases, reported today their financial results for the second quarter of 2024, ended june 30, 2024. financial highlights: 110% net product revenue growth resulted from an increase in arakoda® pharmacy deliveries of 288%, from 331 boxes (q2 2023) to 1,301 boxes (q2 2024).
SXTP Ratings Summary
SXTP Quant Ranking